Isn't this a comparable drug to Perifosine? Read this:
If so we would looke at teh same revenue potential (together with Kerx) Right IF Peri makes it to market.
Hopefully Perifosine will also come out with less side effetcts...
Look at this answer there:
Wrong again buddy. In the KERX study;
Patients must have failed available therapy for the treatment of advanced colorectal cancer, including fluoropyrimidine, irinotecan,oxaliplatin, bevacizumab and for K-ras wild-type (WT) patients,anti-EGFR antibody (cetuximab or panitumumab) containing therapies.
I believe this is the trial document:
Histological or cytological documentation of adenocarcinoma of the colon or rectum
Progression during or within 3 months following the last administration of approved standard therapies. Patients treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy
Patients with measurable or non measurable disease
Eastern Cooperative Oncology Group (ECOG) Performance Status of </= 1
Life expectancy of at least 3 months
Adequate bone marrow, liver and renal function"
This link provides a little more details on the medical findings in their study....
Looks like they offer our heavy pretreated CRC patiens 6 weeks more to live, which of course is basically wonderfull for these patients, but also with serious side effecs. Hope that Perifosine will beat that result and provide even better treatment to the same patients. Perifosine is now doomed to be later in market than Regorafenib, I assume. And that is IF peri makes it to market of course :-)